ShareThis Page

Mylan CEO to testify in hearing on EpiPen price increases

| Wednesday, Sept. 14, 2016, 1:03 p.m.
Heather Bresch, chief operating officer of Mylan Pharmacueticals, sits in her office in Canonsburg on April 8, 2008. Bresch will face lawmakers' questions at a hearing next week on steep price hikes for the company's life-saving EpiPen injector device.
Heather Bresch, chief operating officer of Mylan Pharmacueticals, sits in her office in Canonsburg on April 8, 2008. Bresch will face lawmakers' questions at a hearing next week on steep price hikes for the company's life-saving EpiPen injector device.
Heather Bresch, CEO of Mylan
Heidi Murrin | Trib Total Media
Heather Bresch, CEO of Mylan

Mylan CEO Heather Bresch will appear at a congressional hearing next week to face questions about steep price increases for the lifesaving EpiPen device as the drugmaker begins to turn over requested financial documents, a House committee said Wednesday.

The Oversight and Government Reform Committee is the first of several congressional panels probing the issue to say that Bresch would appear at a hearing. Several committees have sent requests for information to Netherlands-based Mylan, which is run from offices in Cecil, concerning the drug's 500 percent price increase since the company bought the rights to the device in 2007, to $608 for a two-pack.

“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” said Oversight and Government Reform Committee leaders Jason Chaffetz, R-Utah, and Elijah Cummings, D-Md., in a statement announcing Wednesday's hearing.

A spokeswoman for Mylan could not be reached.

The committee announcement said Mylan “indicated that it will begin producing documents this week” in connection with a letter that Chaffetz and Cummings sent to Bresch last month. The letter sought documents and communications regarding Mylan's revenue from EpiPens since 2007, manufacturing costs and how much the company receives from federal health care programs.

In addition to Bresch, the committee lists as a witness at the hearing Doug Throckmorton, deputy director of the Center for Drug Evaluation and research at the Food and Drug Administration. Lawmakers have been critical of the FDA over delays in approving a generic competitor to the EpiPen.

The EpiPen auto injector enjoys a near monopoly in the market.

Prefilled with a small dose of epinephrine, it is used to stop potentially fatal allergic reactions to insect bites and foods such as nuts. Many schools require students with allergies to have them on hand.

Politicians, including Democratic presidential nominee Hillary Clinton, and consumer advocates have accused Mylan of price gouging in a furor that has grown since last month.

The Senate Aging Committee asked Mylan for information and the Senate Permanent Subcommittee on Investigations has taken the first step toward a formal investigation.

Bresch is the daughter of Democratic Sen. Joe Manchin of West Virginia.

In a response last week to questions from Iowa Sen. Chuck Grassley, the Republican chair of the Judiciary Committee, Mylan explained it increased the price to cover the costs of research, advocacy and improvements it made to the product.

The company launched a new version of the EpiPen in 2009 that made it easier to carry, hold and administer the injection, Mylan said.

It also was investing in improving the drug formulation to have a longer shelf life so that consumers would not have to replace unused injectors as frequently.

Grassley called Mylan's seven-page letter “an incomplete response” and said he would keep pressing for answers while working to bring generic competitors to the market.

Chaffetz and Cummings said their committee would look at ways to encourage competition and speed FDA approval of generic alternatives.

“Our goal is to work together to ensure that critical medications, like the EpiPen, are accessible and affordable for all of our constituents,” they wrote.

David Conti is the assistant business editor at the Tribune-Review. Reach him at 412-388-5802 or

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.